Image Source: AsiaOne
Telix and Monrol Expand Alliance to Include Lutetium SupplyGlobeNewswireMay 10, 2021MELBOURNE, Australia and ISTANBUL, Turkey, May 10, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered a global clinical supply agreement with Istanbul-based Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) for no carrier added (NCA) lutetium-177 (177Lu), a key therapeutic isotope used in Telix’s portfolio of Molecularly Targeted Radiation (MTR) products.
Source: AsiaOne